evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,429 questions · 3,558 findings · 436 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 660 · 18.5%GRADE not reported 375 · 10.5%Very low 727 · 20.4%Low 887 · 24.9%Moderate 709 · 19.9%High 200 · 5.6%

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Intervention not reported

Cramp frequency (percentage change from baseline at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations

The intervention showed no clear difference in cramp frequency (percentage change from baseline at 4 weeks) (moderate certainty).

1 finding from 1 review

Intervention not reported

Cramp frequency (responder analysis: 25% or better reduction at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations

The intervention showed no clear difference in cramp frequency (responder analysis: 25% or better reduction at 4… (high certainty).

1 finding from 1 review

Intervention not reported

Cramp frequency (mean number of cramps per week on treatment at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations

The intervention showed no clear difference in cramp frequency (mean number of cramps per week on treatment at 4… (moderate certainty).

1 finding from 1 review

Intervention not reported

Cramp intensity (moderate or worse at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations

The intervention showed no clear difference in cramp intensity (moderate or worse at 4 weeks) (moderate certainty).

1 finding from 1 review

Intervention not reported

Cramp duration (≥ 1 minute at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations

The intervention showed no clear difference in cramp duration (≥ 1 minute at 4 weeks) (low certainty).

1 finding from 1 review

Intervention not reported

Major adverse events · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations

It is very uncertain whether the intervention changes major adverse events (very low certainty).

1 finding from 1 review

Intervention not reported

Minor adverse events · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations

The intervention showed no clear difference in minor adverse events (low certainty).

1 finding from 1 review